News
PLRX
1.000
+1.01%
0.010
Weekly Report: what happened at PLRX last week (0928-1002)?
Weekly Report · 3d ago
PLRX’s FORTIFY Trial: Early Oncology Bet With Upside for Immune-Oncology Investors
TipRanks · 6d ago
Pliant Therapeutics Names David Raben As CMO To Lead PLN-101095 Development
NASDAQ · 10/01 09:00
*Pliant Therapeutics: Appoints David Raben, M.D., as Chief Medical Officer
Dow Jones · 09/30 20:12
Press Release: Pliant Therapeutics Appoints David Raben, M.D., as Chief Medical Officer
Dow Jones · 09/30 20:10
Weekly Report: what happened at PLRX last week (0921-0925)?
Weekly Report · 09/28 10:06
Weekly Report: what happened at PLRX last week (0914-0918)?
Weekly Report · 09/21 10:06
Weekly Report: what happened at PLRX last week (0907-0911)?
Weekly Report · 09/14 10:10
Weekly Report: what happened at PLRX last week (0831-0904)?
Weekly Report · 09/07 10:05
Weekly Report: what happened at PLRX last week (0824-0828)?
Weekly Report · 08/31 10:11
Weekly Report: what happened at PLRX last week (0817-0821)?
Weekly Report · 08/24 10:12
Here's Why We're Watching Pliant Therapeutics' (NASDAQ:PLRX) Cash Burn Situation
Simply Wall St · 08/19 10:15
Pliant Therapeutics receives Fast Track designation from FDA for PLN-101095
TipRanks · 08/18 12:45
Pliant Therapeutics Receives Fast Track Designation From FDA For PLN-101095 In Combination With Pembrolizumab For Potential Treatment Of Solid Tumors
Benzinga · 08/18 12:35
Analysts Offer Insights on Healthcare Companies: Quoin Pharmaceuticals (QNRX) and Pliant Therapeutics (PLRX)
TipRanks · 08/18 09:50
Weekly Report: what happened at PLRX last week (0810-0814)?
Weekly Report · 08/17 10:12
Canaccord Genuity Sticks to Its Hold Rating for Pliant Therapeutics (PLRX)
TipRanks · 08/13 11:18
Oppenheimer Sticks to Their Hold Rating for Pliant Therapeutics (PLRX)
TipRanks · 08/13 07:25
RBC Capital Sticks to Their Hold Rating for Pliant Therapeutics (PLRX)
TipRanks · 08/12 11:07
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Tecan Group AG (OtherTCHBF), Kyverna Therapeutics, Inc. (KYTX) and Pliant Therapeutics (PLRX)
TipRanks · 08/12 08:50
More
Webull provides a variety of real-time PLRX stock news. You can receive the latest news about Pliant Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About PLRX
Pliant Therapeutics, Inc. is a late-stage biotechnology company, which is focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. The Company’s lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of avb6 and avb1 integrins that is in development in the lead indication for the treatment of idiopathic pulmonary fibrosis, or idiopathic pulmonary fibrosis (IPF). The Company’s second clinical program, PLN-101095, is a small molecule, dual selective inhibitor of integrins avb8 and avb1 for the treatment of solid tumors that are resistant to immune checkpoint inhibitors. Its Phase 1-ready program PLN-101325, is in development for treatment of muscular dystrophies, including Duchenne muscular dystrophy. PLN-101325 is a monoclonal antibody designed to act as an allosteric agonist of integrin a7b1.